Register by November 6! ➡ Learn more: https://lnkd.in/e4Xh5k-W
New funding opportunity: Canadian Consortium on Neurodegeneration in Aging Phase III Research Teams CIHR & partners are investing over CA $16M and AU $3M in grants to study neurodegeneration in aging. Register by November 6. Learn more: https://lnkd.in/e4Xh5k-W
Understanding the history of clinical research helps us to learn lessons and ensure we do better in the future. This week, Dr Heidi Green looks back at the history of clinical research. We’ve come a long way from the four bodily humors (blood, phlegm, yellow bile, and black bile) to oranges and lemons, and the first randomised controlled trial. What will we do better in the future? Read the full post here: https://lnkd.in/eN5gn6CZ #ClinicalResearchHistory #EvolutionOfClinicalResearch #HealthResearchEquity #TheCOUCHWay
How familiar are you with the history of #clinicalresearch? Read this article to find out.
Understanding the history of clinical research helps us to learn lessons and ensure we do better in the future. This week, Dr Heidi Green looks back at the history of clinical research. We’ve come a long way from the four bodily humors (blood, phlegm, yellow bile, and black bile) to oranges and lemons, and the first randomised controlled trial. What will we do better in the future? Read the full post here: https://lnkd.in/eN5gn6CZ #ClinicalResearchHistory #EvolutionOfClinicalResearch #HealthResearchEquity #TheCOUCHWay
Manager, Safety Analysis Scientist at Johnson & Johnson Innovative Medicine. /Translational & Expt research. Immunology, Cell and Molecular Biology. Virology, inflammatory and infectious disease expert/ Leader.
Today, I celebrate yet another significant achievement as we unraveled the potential of interleukin-26 as both a biomarker and a target for therapeutic intervention in severe asthma. Much gratitude to the dedicated team at KI whose relentless efforts brought this breakthrough to fruition. The essence of scientific exploration transcends mere discovery; it embodies the profound dedication of passionate researchers in piecing together intricate puzzles at the microcosmic level, even amidst apparent impossibilities. These incremental advancements, forged through dedication and perseverance, have paved the way for some of the most transformative breakthroughs, that have addressed some of humanity's most pressing health challenges today. Happy reading -:) chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://lnkd.in/dnsmpaZt
Great pub by Hughes & Albert Garcia-Romeu, PhD tackling an important issue historically endemic to psychedelic research. We found the same outcomes when conducting the Global Psychedelic Survey 2023 (GPS 2023; https://lnkd.in/gs4_X9CN), which is why for GPS 2025 were honored to work with academics around the globe to make it available in Spanish, Portuguese, Italian, Farsi, Hebrew, Polish, German and French…with more languages to come!. We hope this will increase the diversity of respondents, and fill important gaps of knowledge re. psychedelic access and use in non-anglophone populations all over the world. #psychedelicscience #equitableaccess #colorfulworld #gps2025
CPCR assistant director Dr. Albert Garcia-Romeu, PhD and colleague Dr. Marcus Hughes published a review of ethnoracial inclusion in clinical trials of psychedelics as a follow up to Michaels et al., 2018 paper. https://lnkd.in/eD8H4XGm "Underrepresentation of ethnoracial minoritized populations persists in studies examining psychedelic therapies, despite growing calls for diversity. Non-Hispanic White participants remain an over-represented majority by a large margin, though, there were greater proportions of ethnic minoritized populations included in studies since 2018, particularly in studies conducted in the USA. This indicates progress towards equity in psychedelic research, though much work is needed to inform the safety and efficacy of psychedelic treatments in the general population."
NEW Business Trip Podcast: “Chemical Conversations: Comparing Psychedelic Compounds in Therapy” We get into some of the big unanswered questions in the psychedelic industry today. Full episode here: https://lnkd.in/gb2w4csh
Investor in frontier mental and brain health tech. Cofounder at PsyMed Ventures and Business Trip.
I hosted (and recorded) a panel at The Battery with psychedelic research pros Allison Feduccia, PhD, Matthew Baggott, PhD, and Nolan Williams. We covered a lot of topics, including: -The effects and mechanisms of different psychedelics (MDMA, psilocybin, ibogaine) -The role of therapy during psychedelic experiences -Digital solutions, new care models, policy changes Listen here: https://lnkd.in/gSEpzwav
COO and Director of R&D @ Salix Sciences | R&D and Innovation | Psychedelics | Food | Pharma | Nutraceuticals
This review provides crucial insights into the ongoing issue of underrepresentation in clinical trials for psychedelic-assisted treatments. By highlighting the dominance of non-Hispanic White participants and the significant underrepresentation of Black, Asian, Latinx, and Indigenous populations, the authors draw attention to a pressing need in the field. Addressing this disparity is not only a matter of ensuring the #safety and #efficacy of treatments for all populations but also a step towards promoting #health #equity. Future #research must prioritize #diversity in study participants to develop more universally applicable and effective psychedelic-assisted therapies. #psychedelic #research #clinicaltrials
CPCR assistant director Dr. Albert Garcia-Romeu, PhD and colleague Dr. Marcus Hughes published a review of ethnoracial inclusion in clinical trials of psychedelics as a follow up to Michaels et al., 2018 paper. https://lnkd.in/eD8H4XGm "Underrepresentation of ethnoracial minoritized populations persists in studies examining psychedelic therapies, despite growing calls for diversity. Non-Hispanic White participants remain an over-represented majority by a large margin, though, there were greater proportions of ethnic minoritized populations included in studies since 2018, particularly in studies conducted in the USA. This indicates progress towards equity in psychedelic research, though much work is needed to inform the safety and efficacy of psychedelic treatments in the general population."
The strength of the OCCAMS consortium lies in its diversity, bringing together the ideal team of researchers, clinicians and patient advocates. Together, with your support, they have the potential to make breakthrough discoveries that could ultimately lead to the eradication of multiple sclerosis. Our world-class research wouldn’t be possible without the exceptional support of people like you. Click here to make a meaningful impact: https://ow.ly/3cWJ50TQpO4
We are delighted to launch our Autumn 2024 issue of RARE Revolution Magazine. Sponsored by UCB this edition, RARE mitochondria, dives into the fundamental role of mitochondria in our health as well as the scientific explosion in the land of mitochondrial research in this relatively new field. Most of all though, is an issue full of hope as the mighty mito community are reimagining their futures, one collaborative step at a time. Read the full issue here: https://lnkd.in/eUEYnPTB RareDisease #MitochondrialDisorders
Bravo RARE Revolution Magazine for highlighting rare diseases and the plight of families fighting to find life-saving treatment solutions for their loved ones. Our CEO, Simon Estcourt, at TMC Pharma Services Ltd, provides insight on page 60 in this edition, of the future of the rare disease landscape and how clinical research organisations, such as TMC, can provide valuable support in this specialist area. #TMC #RareDiseases #CRO #ClinicalResearchOrganisation
We are delighted to launch our Autumn 2024 issue of RARE Revolution Magazine. Sponsored by UCB this edition, RARE mitochondria, dives into the fundamental role of mitochondria in our health as well as the scientific explosion in the land of mitochondrial research in this relatively new field. Most of all though, is an issue full of hope as the mighty mito community are reimagining their futures, one collaborative step at a time. Read the full issue here: https://lnkd.in/eUEYnPTB RareDisease #MitochondrialDisorders
